Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Stage, Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older

NCT05007951 is registered in ClinicalTrials.gov with SK Bioscience Co., Ltd. as lead sponsor.

NCT NCT05007951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05007951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Stage, Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older
Lead sponsor
SK Bioscience Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2021
Completion date
October 2, 2023
Enrollment
4,036 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

covid19